Patents by Inventor San-Bao Hwang
San-Bao Hwang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10406120Abstract: The present invention provides methods for treating glomerulosclerosis such as focal segmental glomerulosclerosis (FSGS) or glomerulonephritis such as immunoglobulin A nephropathy (IgAN) by cyclohexenone compounds.Type: GrantFiled: March 2, 2016Date of Patent: September 10, 2019Assignee: Golden Biotechnology CorporationInventors: Sheng-Yung Liu, San-Bao Hwang
-
Publication number: 20160184239Abstract: The present invention provides methods for treating glomerulosclerosis such as focal segmental glomerulosclerosis (FSGS) or glomerulonephritis such as immunoglobulin A nephropathy (IgAN) by cyclohexenone compounds.Type: ApplicationFiled: March 2, 2016Publication date: June 30, 2016Inventors: Sheng-Yung LIU, San-Bao Hwang
-
Publication number: 20150306047Abstract: The present invention provides methods for treating glomerulosclerosis such as focal segmental glomerulosclerosis (FSGS) or glomerulonephritis such as immunoglobulin A nephropathy (IgAN) by cyclohexenone compounds.Type: ApplicationFiled: January 20, 2012Publication date: October 29, 2015Inventors: Sheng-Yung Liu, San-Bao Hwang
-
Patent number: 8309611Abstract: The present invention provides methods and compositions for treating lung cancer by cyclohexenone compounds.Type: GrantFiled: March 23, 2011Date of Patent: November 13, 2012Assignee: Golden Biotechnology CorporationInventors: Sheng-Yung Liu, San-Bao Hwang, Wu-Che Wen
-
Patent number: 8153167Abstract: A composition derived from six plant materials: ((i) Herba epimedii (Yin Yang Huo) (ii) Fructus Psoraleae (Psoralea coryfolia) (Bu Gu Zhi) (iii) Radix Rehmanniae preparatae (Rehmannia glutinosa) (Shu Di) (iv) Cortex Eucommiae (Du Zhong) (v) Fructus Cnidii (She Chuang Zhi) (vi) Radix Astragali (Astragalus Membranaceus) (Huang Qi)) is useful in treating conditions linked to the activity of osteoblasts and/or osteoclasts, such as osteoporosis and other conditions relating to bone mass or the menopause; obesity; glucose intolerance; and diabetes.Type: GrantFiled: November 19, 2008Date of Patent: April 10, 2012Assignee: Medipearl Pte Ltd.Inventors: San-Bao Hwang, Priya Gupta, Shiau Chuen Cheah
-
Publication number: 20120071426Abstract: The present invention provides methods and compositions for treating lung cancer by cyclohexenone compounds.Type: ApplicationFiled: March 23, 2011Publication date: March 22, 2012Applicant: Golden Biotechnology CorporationInventors: Sheng-Yung Liu, San-Bao Hwang, Wu-Che Wen
-
Publication number: 20090186102Abstract: A composition derived from six plant materials: ((i) Herba epimedii ??? (Yin Yang Huo) (ii) Fructus Psoraleae (Psoralea coryfolia) ??? (Bu Gu Zhi) (iii) Radix Rehmanniae preparatae (Rehmannia glutinosa) ??? (Shu Di) (iv) Cortex Eucommiae ?? (Du Zhong) (v) Fructus Cnidii ??? (She Chuang Zhi) (vi) Radix Astragali (Astragalus Membranaceus) ?? (Huang Qi)) is useful in treating conditions linked to the activity of osteoblasts and/or osteoclasts, such as osteoporosis and other conditions relating to bone mass or the menopause; obesity; glucose intolerance; and diabetes.Type: ApplicationFiled: November 19, 2008Publication date: July 23, 2009Inventors: San-Bao Hwang, Priya Gupta, Shiau Chuen Cheah
-
Publication number: 20080132553Abstract: The present invention relates to methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, and which additionally reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving alpha-dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. Certain useful agents are thiazolium salts. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A novel immunoassay for detection of the reversal of the nonenzymatic crosslinking is also disclosed.Type: ApplicationFiled: December 21, 2007Publication date: June 5, 2008Inventors: Anthony Cerami, Peter C. Ulrich, Dilip R. Wagle, San-Bao Hwang, Sara Vasan, John J. Egan
-
Publication number: 20070025926Abstract: The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, and which additionally reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving alpha-dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. Certain useful agents are thiazolium salts. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A novel immunoassay for detection of the reversal of the nonenzymatic crosslinking is also disclosed.Type: ApplicationFiled: February 9, 2006Publication date: February 1, 2007Inventors: Anthony Cerami, Peter Ulrich, Dilip Wagle, San-Bao Hwang, Sara Vasan, John Egan
-
Publication number: 20060251673Abstract: A method for cultivating Antrodia Camphorata is provided. First, Antrodia Camphorata is pre-incubated on a sloped surface culture medium. A portion of the pre-incubated Antrodia Camphorata is transferred to a liquid culture medium for incubation. Then, Antrodia Camphorata incubated in the liquid culture medium is moved to a solid culture medium for incubation. The cultivated Antrodia Camphorata has similar efficacies for inhibiting cancel cell growth, reducing the occurrence of atherosclerosis or recovering the damaged liver functions, as the wild Antrodia Camphorata.Type: ApplicationFiled: May 5, 2006Publication date: November 9, 2006Inventors: San-Bao Hwang, Yu-Lung Wang, Sheng-Yung Liu
-
Patent number: 7022719Abstract: The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, and which additionally reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving alpha-dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. Certain useful agents are thiazolium salts. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A novel immunoassay for detection of the reversal of the nonenzymatic crosslinking is also disclosed.Type: GrantFiled: April 18, 2003Date of Patent: April 4, 2006Assignee: Alteon, Inc.Inventors: Anthony Cerami, Peter C. Ulrich, Dilip R. Wagle, San-Bao Hwang, Sara Vasan, John J. Egan
-
Publication number: 20040198795Abstract: The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise substituted imidazolium compounds capable of inhibiting the formation of, as well as reversing already formed, advanced glycosylation endproducts of target proteins. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.Type: ApplicationFiled: April 20, 2004Publication date: October 7, 2004Inventors: Dilip R. Wagle, San-Bao Hwang, Veronica M. Mallon, Sara Vasan, John J. Egan, Peter Ulrich, Anthony Cerami
-
Publication number: 20040034074Abstract: The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, and which additionally reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving alpha-dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. Certain useful agents are thiazolium salts. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A novel immunoassay for detection of the reversal of the nonenzymatic crosslinking is also disclosed.Type: ApplicationFiled: April 18, 2003Publication date: February 19, 2004Inventors: Anthony Cerami, Peter C. Ulrich, Dilip R. Wagle, San-Bao Hwang, Sara Vasan, John J. Egan
-
Publication number: 20020192842Abstract: The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, and which additionally reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving alpha-dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. Certain agents useful are thiazolium salts. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A novel immunoassay for detection of the reversal of the nonenzymatic crosslinking is also disclosed.Type: ApplicationFiled: June 19, 2002Publication date: December 19, 2002Inventors: Anthony Cerami, Peter C. Ulrich, Dilip R. Wagle, San-Bao Hwang, Sara Vasan, John J. Egan
-
Publication number: 20020177723Abstract: 2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 2,4-diaryl tetrahydrofurans, 2,4-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes, 2,4-diaryl pyrrolidines, and 2,5-diaryl pyrrolidines are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i. e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase.Type: ApplicationFiled: April 11, 2000Publication date: November 28, 2002Inventors: Xiong Cai, Sajjat Hussoin, San-Bao Hwang, David Killian, T.Y. Shen
-
Patent number: 6440749Abstract: The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, and which additionally reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving alpha-dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. Certain agents useful are thiazolium salts. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A immunoassay for detection of the reversal of the nonenzymatic crosslinking is also disclosed.Type: GrantFiled: December 22, 1999Date of Patent: August 27, 2002Assignees: Alteon. Inc., The Picower Institute for Medical ResearchInventors: Anthony Cerami, Peter C. Ulrich, Dilip R. Wagle, San-Bao Hwang, Sara Vasan, John J. Egan
-
Patent number: 6380192Abstract: The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises a substituted 1,2,4-triazine of the formula (I) and the biologically and pharmaceutically acceptable salts thereof; capable of inhibiting the formation of advanced glycosylation endproducts of target proteins. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.Type: GrantFiled: April 20, 2000Date of Patent: April 30, 2002Assignee: Alteon, Inc.Inventors: Dilip R. Wagle, Michael E. Lankin, San-Bao Hwang
-
Patent number: 6294574Abstract: 2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 2,4-diaryl tetrahydrofurans, 2,4-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes, 2,4-diaryl pyrrolidines, and 2,5-diaryl pyrrolidines are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i. e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. A method to treat disorders mediated by PAF or leukotrienes is also disclosed, that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.Type: GrantFiled: June 6, 1995Date of Patent: September 25, 2001Assignee: Cytomed, Inc.Inventors: Xiong Cai, Sajjat Hussoin, San-Bao Hwang, David Killian, T. Y. Shen
-
Patent number: 6060470Abstract: The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises a substituted 1,2,4-triazine of the formula (I) ##STR1## and the biologically and pharmaceutically acceptable salts thereof; capable of inhibiting the formation of advanced glycosylation endproducts of target proteins. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.Type: GrantFiled: January 20, 1999Date of Patent: May 9, 2000Assignee: Alteon, Inc.Inventors: Dilip R. Wagle, Michael E. Lankin, San-Bao Hwang
-
Patent number: RE38330Abstract: The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises a thiazolium compound capable of inhibiting, and to some extent reversing, the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A novel immunoassay for detection of the reversal of the nonenzymatic crosslinking is also disclosed.Type: GrantFiled: August 12, 1999Date of Patent: November 25, 2003Assignee: Alteon Inc.Inventors: Anthony Cerami, Peter C. Ulrich, Dilip R. Wagle, San-Bao Hwang, Sara Vasan, John J. Egan